

Our Ref: FOI ID 51002

15 August 2018

[southportandformbyccg.foi@nhs.net](mailto:southportandformbyccg.foi@nhs.net)

**NHS Southport & Formby CCG**  
5 Curzon Road  
Southport  
PR8 6PL

Tel : 0151 317 8456

Email: [southportandformby.ccg@nhs.net](mailto:southportandformby.ccg@nhs.net)

## Re: Freedom of Information Request

Please find below the response to your recent Freedom of Information request regarding Branded generic 7-Day Buprenorphine transdermal patches addition to formulary services within NHS Southport and Formby CCG.

### Request/Response:

With respect to the following questions, please provide answers for any decisions made since 1 January 2016.

1. Please identify and state the name of any formulary group that your CCG was part of in 2016? This may include one or more of: a joint formulary committee, area formulary committee or equivalent formulary.

[A pharmacist from NHS Southport and Formby CCG Medicines Management Team is a member of the Pan Mersey formulary and guidelines sub group.](#)

2. On what date was Qdem's 7-day buprenorphine transdermal patch with the product name Butec submitted to any formulary group identified in question "1" above for consideration and approval as to whether it should be included on the respective drug formulary?

3. Where Butec has been added to your CCG's drugs formulary or another formulary identified in question "1", please provide any minutes that evidence what decisions were made in relation to whether to approve or reject Butec's application.

4. On what date was Butec first added to your CCG's drug formulary (adopting the relevant formulary identities listed above)?

5. Assuming the response to question "3" is positive, has any other branded generic 7-day buprenorphine transdermal patch subsequently been added, or replaced Butec on your CCG's drug formulary? Please indicate the date on which this occurred. If the answer to this question is positive, please provide any minutes that evidence what decisions were made in relation to whether to approve or reject an subsequent supplier's branded generic 7-day Buprenorphine transdermal patch application.

6. Please provide a copy of any guidance your CCG possessed in 2016 that established the process by which a new drug would be considered for addition to your CCG's drug formulary (again, adopting the relevant formulary identities listed in question "1").

For questions 2 -6 NHS Southport and Formby CCG do not have a Medicines formulary, the CCG follows the Pan Mersey formulary.

7. Please provide any other minutes recorded by your CCG that evidence what decisions were made by your CCG's medicines management committee or other equivalent committee at CCG level to select a preferred branded generic 7-day Buprenorphine transdermal patch.

The Pan Mersey APC recommend for safety reasons that all transdermal patch preparations should be prescribed by brand name to avoid confusion. NHS Southport and Formby CCG therefore selected Butec as their preferred brand as it was the most cost effective brand in September 2016.

There are no formal minutes regarding the decision to select Butec as the preferred brand of buprenorphine 7 day transdermal patch.